Five things for pharma marketers to know: Friday, May 12, 2017
1. AstraZeneca's immunotherapy drug Imfinzi demonstrated in a Phase-III trial that it reduced the risk of death from advanced lung cancer. The FDA approved Imfinzi to treat advanced bladder cancer on May 1. (Reuters)
2. The Blue Cross Blue Shield Association plans to use ride-sharing company Lyft to help patients get to their doctor's appointments. The service is expected to roll out next month. (MobiHealthNews)
3. Aetna CEO Mark Bertolini said the U.S. should debate moving to a single-payer health system. “We're going to have to pay for it one way or another,” he said. “What we have to do is we have to get the costs right. We have to get people healthy. It's not about who is paying the bill. (Vox)
4. Eli Lilly plans to submit its experimental migraine treatment galcanezumab to the FDA in the second half of 2017. Galcanezumab is part of a new class of antibodies that inhibit the calcitonin gene-related peptide, referred to as CGRP, that's believed to play a role in migraines.
5. The prognosis for HIV patients is improving due to new medicines that are less toxic, and because patients are more adherent to their treatment regimens, according to new study published in The Lancet HIV. (Quartz)